Affiliations: Center for Applied Proteomics and Molecular Medicine,
George Mason University, Manassas, VA, USA
Note: [] Corresponding author: Emanuel Petricoin III, 10900 University
Blvd, Manassas, VA 20155, USA. Tel.: +1 703 993 8646; E-mail:
[email protected]
Abstract: Recent advances in high throughput, high content "omic" technologies
coupled with clinical information has lead to the expectation that the
complexity of the molecular information generated will lead to more robust
scientific research as well as the expectation that overarching therapeutic
approaches will be patient-tailored to the underlying specific molecular
defects of the disease. As disease understanding progresses and more
therapeutics, which predominately target proteins, are developed there is a
need to more confidently determine the protein signaling events that can be
correlated with drug response since the deranged protein signaling networks are
often the drug target itself. In this environment, the Reverse Phase Protein
Microarray (RPMA) can be utilized to address the needs of both clinical
screening and disease understanding through its ability to provide an unmatched
functional and highly multiplexed signaling network level mapping of ongoing
signaling activation, coupled with the ability of the platform to provide this
information reproducibly from a tiny needle biopsy specimen or fine needle
aspirate. This platform has now been utilized for biomarker
discovery/validation and advancements in disease understanding both in the
clinic and at the bench in the fields of cancer, liver disease, immunological
disorders, and bacterial infection.
